gene_symbol
UNKNOWN
binding_type
antigen recognition
cytotoxicity
YES
cytotoxicity_type
DIRECT
cytotoxicity_mechanism
Infused TILs use their endogenous TCRs to recognize tumor neoantigen peptide–HLA class I complexes and directly kill target cells via perforin/granzyme release and death receptor (Fas–FasL) pathways.
enzyme_product
Off
epitope
On
variant
On
isoform
Off
hla_specific
On
gated
Off
other_modifier
Recognized by CD8+ TILs via endogenous TCR; patient-specific peptides presented on HLA-A/B/C
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT05676749
disease_id_num_tar_ref
2052
drug_id_num_tar_ref
5491